Objective To evaluate the efficacy and safety of sequential moxifloxacin therapy in the treatment of patients with community acquired pneumonia.Methods One hundred and sixteen patients with community acquired pneumonia were randomly divided into three groups.In group A (moxifloxacin sequential group),moxifloxacin was administered by intravenous infusion 400 mg/250 ml once daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration at the same dose.The total treatment duration was also 7～12 days.In group B (control group),levofloxacin was administered by intravenous infusion 0.2 g/250 ml twice daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration 0.1 g twice daily.The total treatment duration was also 7～12 days.In group C(control group),ceftriaxone sodium was administered by intravenous infusion 2.0 g/250 ml once daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration Cefpodoxime 0.1 g twice daily with Azithromycin 0.5 g once daily.The total treatment duration was also 7～12 days.Results The overall cure rates and efficacy rates were 70.3%and 86.5% in group A,67.1% and 82.9% in group B,47.2% and 72.2% in group C,respectively.The bacterial clearance rates were 84.8% in group A,82.1% in group B,58.1% in group C,respectively.There was no significant difference(P＞0.05) between group A and group B,and there was significant difference(P＜0.05)between group A and group C in the above results.The time of appearing "clinical standard" of intravenous infusion turned into oral administration were(2.27 ± 1.14)d in group A,(2.33 ± 1.15)d in group B,(3.03 ±1.08)d in group C,respectively.There was no significant difference(P＞0.05)between group A and group B,and there was significant difference(P＜0.05)between group A and group C in the above results.The incidence of adverse drug reactions of three groups were 5.4% 、5.7% and 13.9%,respectively.There was no significant difference (P＞0.05) between group A and group B,and there was significant difference (P＜0.05) between group A and group C in the above results.Conclusion Sequential moxifloxacin therapy in patients with community acquired pneumonia was more effective and safe.